Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 11Tumor-Agnostic 3Breast 3Head & Neck 1Gastrointestinal 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Recurrence 1

Interventions

pembrolizumab 166Cisplatin 112Cetuximab 76Nivolumab 52Carboplatin 51Fluorouracil 48Paclitaxel 42Docetaxel 37Gemcitabine 30Radiotherapy 28Capecitabine 19Cyclophosphamide 18durvalumab 17Injections 17lenvatinib 16atezolizumab 16cemiplimab 15spartalizumab 13fludarabine 13avelumab 12Ipilimumab 12Pemetrexed 11130-nm albumin-bound paclitaxel 11Oxaliplatin 10Gefitinib 10tremelimumab 9Drug Therapy 9tislelizumab 8epacadostat 8budigalimab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × vinflunine × Head & Neck × Clear all
NCT02347332 2019-03-05

Phase III Study of Vinflunine Plus Methotrexate Versus Methotrexate Alone in Patients With Head and Neck Cancer

Pierre Fabre Medicament

Phase 3 Completed
459 enrolled 13 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡